Bringing medical devices to Uzbekistan — without the friction.
We handle state registration under Cabinet of Ministers Resolution No. 738, recognition of approvals held abroad, and the Authorized Representative duties that follow, so your device reaches Uzbek patients sooner.
A new regulatory landscape
Cabinet of Ministers Resolution No. 738 of 24 November 2025 took effect on 26 February 2026 and replaced the 2018 framework. State registration is administered by the Center for Pharmaceutical Products Safety under the Ministry of Health. Devices are sorted into four risk-based safety classes, foreign manufacturers must appoint a locally established Authorized Representative recorded on the State Register, certificates run for five years, and devices already cleared by a reference regulator can use a recognition procedure instead of the full national file.
What we do
End-to-end regulatory execution for manufacturers, distributors and market-access teams.
Reference regulators
A device holding a current approval from the US FDA, an EU CE marking, or a clearance from the UK MHRA, Japan's PMDA or Korea's MFDS may qualify for the recognition procedure. We confirm eligibility against the certificate you actually hold before anything is filed.
- US FDA
- EU CE
- UK MHRA
- Japan PMDA
- Korea MFDS
Credentials and partners
Registrations, memberships and the laboratories, translators and logistics partners we work with on submissions.
Manufacturers we work with
Since 2019 we have carried registration and Authorized Representative work for manufacturers across Asia, Europe and North America — from single-device files to multi-hundred-line reagent portfolios.
- MAGLUMI®
- DiaSorin
- QIAGEN
- Phadia
- Clarius
- Instrumentation Laboratory
- URIT
Not sure which route applies?
Answer four short questions. We will indicate the likely pathway and follow up with a written plan for your product.